Science at Sanofi

The programme brought together international and local experts to discuss the evolving understanding of Type 2 inflammation in atopic dermatitis, with a focus on IL-4 and IL-13, disease modification, and the importance of early intervention across different patient populations. 

The United in Rare: Advancing LSDs Care across Asia event was held on the 22nd to 23rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

Access the full recording of the webinar to gain insights on Atopic Dermatitis, Bullous Pemphigoid, and practical applications from leading experts.

Discover the latest breakthroughs in pediatric infectious diseases, focusing on Pertussis, Polio and Hib protection.

Watch now to gain useful update on the latest in COPD diagnosis and management.​

Chapter 2: Pompe High-Risk Screening in Asia

Chapter 3: Treatment Strategies for Pompe Disease

Experts across Southeast Asia shared insights on influenza in older adults, highlighting disease burden, regional epidemiology, and the crucial role of vaccination for this high-risk group.

Citation: Geba et al. Journal of Allergy and Clinical Immunology 2025;Vol.151: 756-766

Rare Disease Day raises awareness for the 300 million people worldwide living with a rare disease, along with their families and carers. Over 6,000 rare diseases are characterized by a wide range of conditions and symptoms that can vary not only between diseases but also among individuals with the same condition. Take the opportunity to support equitable access to diagnosis, treatment, healthcare, social support for those affected by rare diseases.

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with 
moderate-to-severe atopic dermatitis

LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.

LIBERTY AD HAFT was a randomized phase 3 trial in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis inadequately controlled with topicals.

Efficacy is shown through real-world evidence, skin bacterial microbiome, trans-epidermal water loss (TEWL), and nonatopic comorbidities.